Zobrazeno 1 - 10
of 36
pro vyhledávání: '"J. Antonio G. López"'
Autor:
Lisandro D. Colantonio, Vera Bittner, Monika M. Safford, Santica Marcovina, Todd M. Brown, Elizabeth A. Jackson, Mei Li, J. Antonio G. López, Keri L. Monda, Timothy B. Plante, Shia T. Kent, Paul Muntner, Robert S. Rosenson
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 11 (2022)
Background It is unclear whether lipoprotein(a) is associated with coronary heart disease (CHD) and ischemic stroke events in White and Black adults with atherosclerotic cardiovascular disease (ASCVD). Methods and Results We conducted a case‐cohort
Externí odkaz:
https://doaj.org/article/dee9523a83154151a2146b33a52a1bcd
Autor:
Alberto J. Lorenzatti, Maria Laura Monsalvo, J. Antonio G. López, Huei Wang, Robert S. Rosenson
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-14 (2021)
Abstract Background Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholester
Externí odkaz:
https://doaj.org/article/c7cfa990064d4f37a2d17516c6a6bd2a
Autor:
Matthew T. Mefford, Santica M. Marcovina, Vera Bittner, Mary Cushman, Todd M. Brown, Michael E. Farkouh, Sotirios Tsimikas, Keri L. Monda, J. Antonio G. López, Paul Muntner, Robert S. Rosenson
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 11, Pp 1946-1952 (2019)
The pharmacologic inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) lowers lipoprotein (a) [Lp(a)] concentrations. However, the impact of genetic PCSK9 loss-of-function variants (LOFVs) on Lp(a) is uncertain. We determined the assoc
Externí odkaz:
https://doaj.org/article/d3387648d2aa41bda30df7af0a6912b8
Publikováno v:
Cardiology and Therapy, Vol 8, Iss 1, Pp 91-102 (2019)
Abstract Introduction The apolipoprotein A1 (apoA1) remnant ratio has been identified as an independent cardiovascular (CV) risk factor. Higher apoA1 remnant ratios may predict lower CV risk in some patients. This analysis aimed to evaluate the effec
Externí odkaz:
https://doaj.org/article/942854b6cf564b019dbed79ca1d97cd1
Autor:
Martha L. Daviglus, Keith C. Ferdinand, J. Antonio G. López, You Wu, Maria Laura Monsalvo, Carlos J. Rodriguez
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 1 (2021)
Background Prevalence of cardiovascular disease risk factors and rates of atherosclerotic cardiovascular disease outcomes vary across racial/ethnic groups. This analysis examined the effects of evolocumab on LDL‐C (low‐density lipoprotein cholest
Externí odkaz:
https://doaj.org/article/0730ad92a8bf48beaf116b0962a9365b
Autor:
Peter P. Toth, Steven R. Jones, Maria Laura Monsalvo, Mary Elliott‐Davey, J. Antonio G. López, Maciej Banach
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 5 (2020)
Background Dyslipidemia guidelines recommend non‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein B (ApoB) as additional targets of therapy and consider lipoprotein(a) a significant cardiovascular risk marker. The current a
Externí odkaz:
https://doaj.org/article/5bd70ffd9a2f47c7b2b4e33007fcef41
Autor:
Prakriti Gaba, Michelle L. O’Donoghue, Jeong-Gun Park, Stephen D. Wiviott, Dan Atar, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Gaetano M. De Ferrari, Zbigniew A. Gaciong, Kalman Toth, Ioanna Gouni-Berthold, Jose Lopez-Miranda, François Schiele, François Mach, Jose H. Flores-Arredondo, J. Antonio G. López, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Robert P. Giugliano, Marc S. Sabatine
Publikováno v:
Circulation. 147:1192-1203
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13253a16b49f4776f898e33b3823a98f
https://doi.org/10.1161/circulationaha.122.063399
https://doi.org/10.1161/circulationaha.122.063399
Autor:
Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Jose H. Flores-Arredondo, J. Antonio G. López, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine
Publikováno v:
Circulation. 146:1109-1119
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and ris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbbf9cc5bb13ac2921d8b0595318d0e8
https://doi.org/10.1161/circulationaha.122.061620
https://doi.org/10.1161/circulationaha.122.061620
Autor:
Parag H. Joshi, Santica Marcovina, Kate Orroth, J. Antonio G. López, Shia T. Kent, Robert Kaplan, Katrina Swett, Daniela Sotres-Alvarez, Bharat Thyagarajan, Leandro Slipczuk, Tamar Sofer, Martha L. Daviglus, Gregory A. Talavera, Neil Schneiderman, Carlos J. Rodriguez
Publikováno v:
JAMA Cardiology.
ImportanceLipoprotein(a) (Lp[a]) is a genetically determined risk-enhancing factor for atherosclerotic cardiovascular disease (ASCVD). The Lp(a) distribution among the diverse Hispanic or Latino community residing in the US has not been previously de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a1a55b6b2c366bf6c0a1b6387fce8c0
https://doi.org/10.1001/jamacardio.2023.1134
https://doi.org/10.1001/jamacardio.2023.1134
Autor:
Robert S. Rosenson, J. Antonio G. López, Maria Laura Monsalvo, You Wu, Huei Wang, Santica M. Marcovina
Publikováno v:
Cardiovascular Drugs and Therapy.
Purpose Cholesterol in lipoprotein(a) [Lp(a)-C] is commonly estimated as 30% of the measured Lp(a) mass. However, difficulties in the accurate measurement of Lp(a) mass, along with the inaccuracy of the 30% assumption, produce erroneous values when L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e091782931a162e21a6c0d5a0bfee159
https://doi.org/10.1007/s10557-022-07407-y
https://doi.org/10.1007/s10557-022-07407-y